Eton Pharmaceuticals: 99% Revenue Jump from Rare Diseases and the Path to a 35% Margin

The focus of Eton Pharmaceuticals (ETON) on therapeutics for rare diseases led to a revenue growth of 99% in the second quarter. Management projects an adjusted EBITDA margin of at least 35% for the future. Analysts from H.C. Wainwright and B. Riley reacted to the business data with new price targets of USD 70 each. Pipeline Expansion: Hemangeol and ASN-001 in Focus Eton Pharmaceuticals' (ETON) business model is based on the development and marketing of therapies for rare diseases. The company focuses on closing therapeutic gaps in small patient...